tislelizumab
Tevimbra (tislelizumab) is a PD-1 checkpoint inhibitor from BeOne Medicines for esophageal squamous cell carcinoma, gastric and gastroesophageal junction adenocarcinoma, and non-small cell lung cancer. By releasing the PD-1 brake on T cells, it restores immune attack on tumours, alone or with chemotherapy.
This page is based on FDA prescribing information and the EMA medicine record for tislelizumab, cross-checked with DailyMed and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
A tumour raises a molecular white flag that presses the PD-1 brake on attacking T cells, so the immune patrol stands down. Tislelizumab covers the brake. The flag no longer works, the T cells stay switched on, and they attack the cancer alongside chemotherapy or on their own in later lines of treatment.
In simple terms
T cells are built to destroy abnormal cells, but many cancers protect themselves by displaying ligands PD-L1 and PD-L2 that bind the PD-1 off-switch on T cells. Tislelizumab-jsgr is a monoclonal antibody that binds PD-1 and blocks its engagement by those ligands, preventing the downstream off signal. Freed from suppression, T cells reactivate and attack cancer cells in the esophagus, stomach, and lung.
In depth
Tislelizumab-jsgr is a monoclonal antibody directed against the negative immunoregulatory receptor programmed cell death 1 (PD-1). Upon administration it binds PD-1 and inhibits the binding of PD-1 to its ligands programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2), preventing activation of PD-1 and its downstream signalling pathways. This may restore immune function through activation of T cells and T-cell-mediated immune responses against tumour cells. PD-1 is a transmembrane protein in the immunoglobulin superfamily expressed on activated T cells that negatively regulates T-cell activation and effector function when engaged by its ligands, and it plays an important role in tumour evasion from host immunity.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How tislelizumab releases the PD-1 brake so T cells attack the tumour
- Tislelizumab covers the brake. The flag no longer works, the T cells stay switched on, and they attack the cancer alongside chemotherapy or on their own in later lines of treatment.
- Tislelizumab-jsgr is a monoclonal antibody that binds PD-1 and blocks its engagement by those ligands, preventing the downstream off signal.
- Upon administration it binds PD-1 and inhibits the binding of PD-1 to its ligands programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2), preventing activation of PD-1 and its downstream signalling pathways.
- Freed from suppression, T cells reactivate and attack cancer cells in the esophagus, stomach, and lung.
Target: Programmed death-1 (PD-1) receptor
An inhibitory receptor on activated T cells; when its ligands PD-L1 and PD-L2 engage it, T-cell activation and effector function are suppressed, which tumours exploit to escape immune attack.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- In combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (1 percent or more)
- As a single agent, for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor
- In combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (1 percent or more)
Approved uses in European Union
EMA- In combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for adults with resectable non-small cell lung cancer at high risk of recurrence
- In combination with pemetrexed and platinum-containing chemotherapy, for the first-line treatment of adults with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on 50 percent or more of tumour cells with no EGFR or ALK positive mutations and locally advanced disease not amenable to surgical resection or platinum-based chemoradiation, or metastatic disease
- In combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adults with squamous non-small cell lung cancer with locally advanced disease not amenable to surgical resection or platinum-based chemoradiation, or metastatic disease
- As monotherapy, for the treatment of adults with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy
Official sources
The statements on this page trace back to these records.
- Tevimbra (tislelizumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: TEVIMBRA (tislelizumab) official US label
U.S. National Library of Medicine, DailyMed
- U.S. Food and Drug Administration: tislelizumab prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: tislelizumab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.